Insider · CIK 0001586785
Garry Arthur Neil
ceochairofficerdirector
Files at CLDX (Celldex Therapeutics, Inc.), AVTX (Avalo Therapeutics, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 28, 2026 | AVTX Avalo Therapeutics, Inc. | MOption exercise Common Stock | +64,866 | - | - | 112,006 | Mar 31, 2026 |
| Mar 28, 2026 | AVTX Avalo Therapeutics, Inc. | FTax withholding Common Stock | -21,892 | $13.89 | $304k | 90,114 | Mar 31, 2026 |
| Mar 28, 2026 | AVTX Avalo Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -64,866 | $0.00 | $0 | 64,867 | Mar 31, 2026 |
| Feb 26, 2026 | AVTX Avalo Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +286,000 | $0.00 | $0 | 286,000 | Mar 2, 2026 |
| Jun 5, 2025 | CLDX Celldex Therapeutics, Inc. | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +16,500 | $0.00 | $0 | 16,500 | Jun 9, 2025 |
| Mar 28, 2025 | AVTX Avalo Therapeutics, Inc. | MOption exercise Common Stock | +64,867 | - | - | 64,927 | Apr 1, 2025 |
| Mar 28, 2025 | AVTX Avalo Therapeutics, Inc. | FTax withholding Common Stock | -17,787 | $8.46 | $150k | 47,140 | Apr 1, 2025 |
| Mar 28, 2025 | AVTX Avalo Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | +64,867 | $0.00 | $0 | 129,733 | Apr 1, 2025 |
| Jan 28, 2025 | AVTX Avalo Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +411,000 | $0.00 | $0 | 411,000 | Jan 30, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.